Condition: Small Bowel Cancer · Colorectal Cancer · Appendiceal Cancer · Sponsor: University of California, Davis
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
This description comes directly from the study's public registry record.
Office of Clinical Research · 916-382-6970 · OCRReferral@health.ucdavis.edu
Always discuss trial participation with your own doctor first.
| University of California, Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06101277